Purpose: The present study was performed to identify the theoretical background for optimal use of the bolus tracking system by analyzing the changes in the initial slope of the aortic time-enhancement curve (TEC).

Materials And Methods: We calculated the contrast medium aortic arrival time (TAR), the time to reach the trigger threshold (effective TAR), the slope of the linear equation of the enhancement unit (enhancement rate), and the time to peak aortic enhancement from the TECs of the pharmacokinetic analysis and retrospective clinical study.

Results: In the pharmacokinetic analysis, the enhancement rate-simulated under conditions of injection duration 30 s and iodine load per body weight 500 mg/kg-was 27.1 HU/s. In the clinical study, the enhancement rate was 27.9 +/- 3.0 HU/s. A correlation was found between the TAR and the enhancement rate, indicating that enhancement rates decrease with increasing TAR. It took 22.7 +/- 0.5 s to reach maximum enhancement of the aorta from the trigger threshold of an increase of 100 HU and injection duration at 30 s.

Conclusion: We found that cardiac output differences are strongly dependent on the TAR and that most of the differences disappeared during the phase until effective TAR.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11604-008-0228-9DOI Listing

Publication Analysis

Top Keywords

pharmacokinetic analysis
12
enhancement rate
12
enhancement
9
bolus tracking
8
tracking system
8
clinical study
8
trigger threshold
8
effective tar
8
injection duration
8
tar
6

Similar Publications

Background: Piperine, a secondary metabolite, affects the antihyperlipidemic effect of Ezetimibe (EZ). Hyperlipidemia is one of the independent risk factors for cardiovascular disorders such as atherosclerosis. Antihyperlipidemic drugs are essential for reducing cardiovascular events and patient mortality.

View Article and Find Full Text PDF

Background: Iduronate-2-sulfatase (IDS) deficiency (MPS II; Hunter syndrome) is a disorder that exhibits peripheral and CNS pathology. The blood brain barrier (BBB) prevents systemic enzyme replacement therapy (ERT) from alleviating CNS pathology. We aimed to enable brain delivery of systemic ERT by using molecular BBB-Trojans targeting endothelial transcytosis receptors.

View Article and Find Full Text PDF

Sepsis is a severe infectious disease with high mortality. However, the indicators used to evaluate its severity and prognosis are relatively complicated. The systemic inflammatory response index (SIRI), a new inflammatory indicator, has shown good predictive value in chronic infection, stroke, and cancer.

View Article and Find Full Text PDF

Cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway, is the target for various nonsteroidal anti-inflammatory drugs (NSAIDs) and selective inhibitors known as coxibs. This study focuses on the development of novel imidazole derivatives as COX-2 inhibitors, utilizing a Structure-Activity Relationship (SAR) approach to enhance binding affinity and selectivity. Molecular docking was performed using Autodock Vina, revealing binding energies of -6.

View Article and Find Full Text PDF

Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients.

Clin Pharmacokinet

January 2025

College of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.

Background And Objective: Telmisartan exhibits significant pharmacokinetic (PK) variability, but it remains unclear whether its PK profile is altered in hypertensive patients. This study aimed to characterize telmisartan PKs by conducting a meta-analysis and developing a pooled population PK model based on data from healthy subjects and hypertensive patients.

Methods: Relevant literature was identified by a systematic approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!